(3-碘丙基)(三甲基)硅烷 | 18135-48-3

• 分子结构分类: 有机化合物 - 有机盐 - 有机金属盐
• 中文名称: (3-碘丙基)(三甲基)硅烷
• 英文名称: (3-iodopropyl)trimethylsilane
• 英文别名: Silane, (3-iodopropyl)trimethyl-；3-iodopropyl(trimethyl)silane
• CAS: 18135-48-3
• 化学式: C₆H₁₅ISi
• 分子量: 242.175
• InChiKey: RVLGUXNVMKOVQM-UHFFFAOYSA-N

物化性质

• 沸点：
  191-192 °C(Press: 744 Torr)
• 密度：
  1.3256 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  3.15
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 海关编码：
  2931900090

反应信息

• 作为反应物：
  描述：

  (3-碘丙基)(三甲基)硅烷 在 18-冠醚-6 氢氧化钾 作用下， 以 甲苯 、 苯 为溶剂， 反应 10.0h， 生成 Trimethyl-[3-(3-prop-2-ynylbenzimidazol-1-ium-1-yl)propyl]silane;bromide
  参考文献：
  名称：

  Synthesis and antitumour activity of trimethylsilylpropyl substituted benzimidazoles

  摘要：

  The quaternisation of N-substituted benzimidazoles by heating with various alkyl, allyl, propargyl and benzyl chlorides and bromides leads to the formation of benzimidazolinium salts. The interaction of N-monosubstituted benzimidazoles with various salts (CuCl2, ZnCl2, CoCl2, PdCl2, and AgNO3) Yielded stable sol-id complexes. Potential cytotoxic activity of synthesised benzimidazolinium salts and benzimidazole metal complexes was tested in vitro on four monolayer tumour cell Hues: MG-22A (mouse hepatoma), HT-1080 (human fibrosarcoma), B16 (mouse melanoma), Neuro 2A (mouse neuroblastoma) and normal mouse fibroblast cells. A preliminary analysis of the structure-activity relationship for the benzimidazole derivatives clearly indicates that the character of substituents in the benzimidazole ring has strong influence on the cytotoxic activity. The insertion of the silicon atom into the N-alkyl chain increases the cytotoxic activity of benzimidazolinium salts significantly, which show a very significant potency in vitro against all studied tumour cell lines, being particularly active in experiments with B16 (mouse melanoma). TD, for the most active compounds are in the range 0.001-0.008 mug ml(-1). Cytotoxicity of benzimidazole metal complexes (L2MX2) strongly depends on the metal nature. 1-(3-Trimethylsilylpropyl)benzimidazole in dose 1 mg kg(-1) inhibits carcinoma S-180 tumour growth by 62% (on ICR mice). (C) 2001 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(01)01241-7
• 作为产物：
  描述：

  3-(三甲硅基)-1-丙醇 在 sodium iodide 作用下， 以 吡啶 、 丙酮 为溶剂， 生成 (3-碘丙基)(三甲基)硅烷
  参考文献：
  名称：

  A cyclopentanone annulation via intramolecular acylation of alkylsilanes

  摘要：

  DOI：

  10.1021/jo00180a041

文献信息

• Silicon compounds derived from ascorbic acid
  申请人：L'Oreal S.A.

  公开号：US06780888B1

  公开（公告）日：2004-08-24

  The invention concerns novel silicon compounds derived from ascorbic acid consisting of a silicon-containing chain or of silanes, comprising at least a radical A of formula (I) wherein: at least one of the radicals L is a divalent radical for fixing A on the silicon chain. The invention further concerns methods for preparing said compounds, compositions, in particular cosmetic or pharmaceutical, containing them, and their use as antioxidant and/or anti-free radical agent, particularly for treating oxidant stress, for treating the effects of exposure to the sun and for preventing ageing.

  这项发明涉及从抗坏血酸衍生的新型硅化合物，包括含硅链或硅烷的化合物，至少包括式(I)的基团A，其中：基团L中至少有一个是用于将A固定在硅链上的二价基团。该发明还涉及制备所述化合物的方法，包含它们的组合物，特别是化妆品或药用品，以及它们作为抗氧化剂和/或抗自由基剂的用途，特别用于治疗氧化应激，治疗暴露于阳光下的影响以及预防衰老。
• Organometallic photochemistry photochemistry of some acyclic ketosilanes
  作者：Henry G. Kuivila、Perry L. Maxfield

  DOI：10.1016/s0022-328x(00)81715-5

  日期：1967.10

  Photolysis of a series of silyl ketones with the general structure (CH3)3Si(CH2)nCOR with n = 0–4, R = C6H5 and with n = 0–3, R = CH3 has been investigated. When n = 3 or 4 a major course of reaction is the Type II cleavage. When R = CH3 and n = 3 a substantial amount of cyclobutanol formation occurs; none is detected when R = C6H5. If n = 2 and R = C6H5 the only photoreactions established are reductive

  具有通式结构的一系列甲硅烷基酮的光解（CH 3）3 SI（CH 2）ñ COR与Ñ = 0-4，R = C 6 H ^ 5，并用Ñ = 0-3，R = CH 3已经调查。当n = 3或4时，反应的主要过程是II型裂解。当R = CH 3且n = 3时，会形成大量的环丁醇。当R ＝ C 6 H 5时，没有检测到。如果n = 2且R = C 6 H 5唯一建立的光反应是还原性烷基化（通过溶剂环己烷）和羰基亚甲基键的裂解。如果R ＝ CH 3，则可以在羰基-亚甲基键的初始裂解的基础上使所有分离出的产物合理化。在惰性溶剂中，n = 1或0的化合物几乎不会发生光化学分解。但是，每种化合物都容易进行光催化水解以形成三甲基硅烷醇和醛或酮。
• Radical addition reactions of alkenylsilanes
  作者：A. W. P. Jarvie、R. J. Rowley

  DOI：10.1039/j29710002439

  日期：——

  bond in three series of alkenylsilanes, R3Si·[CH2]n·CHCH2(R = Me, Ph, or Cl) toward addition by the trichloromethyl radical have been determined, and the relative reactivities of vinyl- and allyltrimethylsilane toward free radical addition by n-dodecanethiol have been investigated. The factors influencing the reactivities of the various alkenylsilanes toward radical addition reagents are discussed.

  已经发现氯仿和四氯化碳加到三甲基-和三苯基-烯丙基硅烷中。确定了三个系列的烯基硅烷R 3 Si·[CH 2 ] n ·CH CH 2（R = Me，Ph或Cl）对三氯甲基自由基加成的双键的相对反应性，并且相对反应性已经研究了乙烯基-和烯丙基三甲基硅烷对正十二烷硫醇自由基加成的影响。讨论了影响各种烯基硅烷对自由基加成剂的反应性的因素。
• Improved method for the preparation of nonyl acridine orange analogues and utilization in detection of cardiolipin
  作者：Pavels Dimitrijevs、Ilona Domracheva、Pavel Arsenyan

  DOI：10.1039/d0nj02116d

  日期：——

  and quantification of cardiolipin (CL). Optimized conditions allow the effective synthesis of NAO analogues with good yield and excellent purity. The introduction of a 3-(trimethylsilyl)propyl moiety improves the dye's solubility and stability in buffer solution and increases its emission intensity by ≈30%. The novel dye can be used for the selective quantification of CL in a liposomal inner mitochondrial

  本研究旨在开发一种快速便捷的方法来制备10-壬基a啶橙（NAO）及其甲硅烷基类似物，以改善其光物理特性，以检测和定量心磷脂（CL）。优化的条件可以高效合成NAO类似物，并具有良好的收率和优异的纯度。3-（三甲基甲硅烷基）丙基部分的引入提高了染料在缓冲溶液中的溶解度和稳定性，并使发光强度增加了约30％。与NAO相比，该新型染料可用于脂质体线粒体内膜模型中CL的选择性定量，其荧光强度和线性斜率更大。新型的含硅NAO类似物具有较低的细胞毒性，并且是用于细胞染色的方便的荧光染料。
• [EN] COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LA PRÉVENTION ET/OU LE TRAITEMENT D'UNE MALADIE MITOCHONDRIALE, NOTAMMENT L'ATAXIE DE FRIEDREICH
  申请人：STEALTH BIOTHERAPEUTICS CORP

  公开号：WO2021202986A1

  公开（公告）日：2021-10-07

  The disclosure provides therapeutic compounds, compositions (e.g., therapeutic agents or medicaments) and methods for preventing or treating mitochondrial disease such as Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with mitochondrial disease, such as Friedreich's ataxia, and/or reducing the likelihood or severity of mitochondrial disease such as Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions. In some instances, the intermediates may themselves by therapeutic agents or prodrugs of therapeutic agents (e.g. reduced forms of the therapeutic compounds).

  该披露提供了治疗化合物、组合物（例如治疗剂或药物）和方法，用于预防或治疗哺乳动物主体中的线粒体疾病，如弗里德赖希共济失调，减少与线粒体疾病（例如弗里德赖希共济失调）相关的风险因素、症状和/或症状，并/或减少线粒体疾病（例如弗里德赖希共济失调）的发生可能性或严重程度。该披露还提供了用于生产上述治疗组合物的新型中间体。在某些情况下，这些中间体本身可能是治疗剂或治疗剂的前药（例如治疗化合物的还原形式）。